LENZ Key Statistics, Chart & Performance
The current stock price of LENZ is 16.48 USD. In the past month the price decreased by -40.93%. In the past year, price decreased by -29%.
LENZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.36 | 984.62B | ||
| JNJ | JOHNSON & JOHNSON | 19.68 | 492.24B | ||
| MRK | MERCK & CO. INC. | 12.2 | 266.67B | ||
| PFE | PFIZER INC | 7.87 | 143.11B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.09 | 108.02B | ||
| ZTS | ZOETIS INC | 20.41 | 57.01B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.65 | 22.89B | ||
| VTRS | VIATRIS INC | 5.31 | 14.25B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.01 | 11.45B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.64B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.56B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.57B |
Related stock screener links
About LENZ
Company Profile
LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. The company is headquartered in Solana Beach, California and currently employs 42 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Company Info
LENZ THERAPEUTICS INC
201 Lomas Santa Fe Drive, Suite 300
Solana Beach CALIFORNIA US
Employees: 42
Phone: 18589257000
LENZ THERAPEUTICS INC / LENZ FAQ
Can you describe the business of LENZ THERAPEUTICS INC?
LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. The company is headquartered in Solana Beach, California and currently employs 42 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Can you provide the latest stock price for LENZ THERAPEUTICS INC?
The current stock price of LENZ is 16.48 USD. The price increased by 3% in the last trading session.
What is the dividend status of LENZ THERAPEUTICS INC?
LENZ does not pay a dividend.
How is the ChartMill rating for LENZ THERAPEUTICS INC?
LENZ has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists LENZ stock?
LENZ stock is listed on the Nasdaq exchange.
How is the market expecting LENZ stock to perform?
14 analysts have analysed LENZ and the average price target is 54.06 USD. This implies a price increase of 228.03% is expected in the next year compared to the current price of 16.48.
When does LENZ THERAPEUTICS INC (LENZ) report earnings?
LENZ THERAPEUTICS INC (LENZ) will report earnings on 2026-03-09, after the market close.
LENZ Technical Analysis
LENZ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LENZ. No worries on liquidiy or solvency for LENZ as it has an excellent financial health rating, but there are worries on the profitability.
LENZ Financial Highlights
Over the last trailing twelve months LENZ reported a non-GAAP Earnings per Share(EPS) of -2.09. The EPS increased by 70.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.11% | ||
| ROE | -25.39% | ||
| Debt/Equity | 0 |
LENZ Forecast & Estimates
14 analysts have analysed LENZ and the average price target is 54.06 USD. This implies a price increase of 228.03% is expected in the next year compared to the current price of 16.48.